Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: A meta-analysis

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 492-495

  Li, Wenlong ^a   Xu, Jing ^a   Wang, Xiaojian ^a   Chen, Jingzhou ^a   Zhang, Channa ^a   Sun, Kai ^a   Hui, Rutai ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Coronary artery disease; Cyclooxygenase 2; Ischemic stroke; Meta analysis

Indexed keywords

CYCLOOXYGENASE 2; CYTIDINE; GUANOSINE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DOMINANT INHERITANCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; PROTECTION; RECESSIVE INHERITANCE; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CORONARY DISEASE; CYCLOOXYGENASE 2; EVIDENCE-BASED MEDICINE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 70450246209     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.029     Document Type: Article

References (30)

1. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 (1995) 2844-2850
2. Belton O.A., Duffy A., Toomey S., and Fitzgerald D.J. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108 (2003) 3017-3023
3. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
4. Schonbeck U., Sukhova G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
5. Linton M.F., and Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 4 (2004) 116-123
6. Bunting S., Gryglewski R., Moncada S., and Vane J.R. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 12 (1976) 897-913
7. Cipollone F., Prontera C., Pini B., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104 (2001) 921-927
8. Cipollone F., Fazia M., Iezzi A., et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107 (2003) 1479-1485
9. Papafili A., Hill M.R., Brull D.J., et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22 (2002) 1631-1636
10. Cipollone F., Toniato E., Martinotti S., et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291 (2004) 2221-2228
11. Colaizzo D., Fofi L., Tiscia G., et al. The COX-2 G/C-765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis 17 (2006) 93-96
12. Hegener H.H., Diehl K.A., Kurth T., et al. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J Thromb Haemost 4 (2006) 1718-1722
13. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
14. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
15. Lee C., and Kong M. An interactive association of common sequence variants in the neuropeptide Y gene with susceptibility to ischemic stroke. Stroke 38 (2007) 2663-2669
16. Kohsaka S., Volcik K.A., Folsom A.R., et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196 (2008) 926-930
17. Huuskonen K.H., Kunnas T.A., Tanner M.M., et al. COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm 2008 (2008) 289453
18. Lee C.R., North K.E., Bray M.S., et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 83 (2008) 52-60
19. Morgan T.M., Krumholz H.M., Lifton R.P., and Spertus J.A. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 297 (2007) 1551-1561
20. Lemaitre R.N., Rice K., Marciante K., et al. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 204 (2009) e58-63
21. Burleigh M.E., Babaev V.R., Oates J.A., et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823
22. Nogawa S., Zhang F., Ross M.E., and Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17 (1997) 2746-2755
23. Iadecola C., Niwa K., Nogawa S., et al. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98 (2001) 1294-1299
24. Dore S., Otsuka T., Mito T., et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 54 (2003) 155-162
25. Andersohn F., Schade R., Suissa S., and Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 37 (2006) 1725-1730
26. Whelton A., White W.B., Bello A.E., Puma J.A., and Fort J.G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
27. Walter M.F., Jacob R.F., Day C.A., et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 177 (2004) 235-243
28. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
29. Cipollone F., and Patrono C. Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?. Arterioscler Thromb Vasc Biol 22 (2002) 1516-1518
30. Corella D., Gonzalez J.I., Bullo M., et al. Polymorphisms cyclooxygenase-2-765G>C and interleukin-6-174G>C are associated with serum inflammation markers in a high cardiovascular risk population and do not modify the response to a Mediterranean diet supplemented with virgin olive oil or nuts. J Nutr 139 (2009) 128-134